{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:10:01Z","timestamp":1756361401717,"version":"3.44.0"},"reference-count":9,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,10,21]]},"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>A 27-year-old man with a background of schizophrenia presented during the summer months with a 2-day history of a blistering eruption predominantly affecting his hands, forearms and face. He had not knowingly been exposed to any chemicals or toxins and was otherwise well. Clinical examination revealed multiple, large, tense blisters affecting the sun-exposed sites. Histology subsequently demonstrated subepidermal blisters with minimal inflammation and negative immunofluorescence. Porphyrin biochemistry including faecal, urinary and serum samples were unremarkable and thus a diagnosis of pseudoporphyria was reached. There were no obvious triggers, however, olanzapine (an atypical antipsychotic) had been commenced 2 months previously and was deemed to be the most likely cause. This is the first report of pseudoporphyria being associated with an atypical antipsychotic and highlights the importance of eliciting an accurate drug history by specifically enquiring about any recent medication changes that could account for the clinical presentation.<\/jats:p>","DOI":"10.1136\/bcr-2019-232263","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T10:06:07Z","timestamp":1572689167000},"page":"e232263","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["An unusual bullous eruption: olanzapine induced pseudoporphyria"],"prefix":"10.1136","volume":"12","author":[{"given":"Oliver Ross","family":"Johnson","sequence":"first","affiliation":[{"name":"Internal Medicine, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Felicity","family":"Stewart","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, Salford Royal NHS Foundation Trust, Salford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arti","family":"Bakshi","sequence":"additional","affiliation":[{"name":"Histopathology, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Weston","sequence":"additional","affiliation":[{"name":"Endocrinology, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,11,2]]},"reference":[{"key":"2025082722521688000_12.11.e232263.1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1529-8019.2003.01631.x"},{"key":"2025082722521688000_12.11.e232263.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.03.001"},{"key":"2025082722521688000_12.11.e232263.3","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.111338"},{"key":"2025082722521688000_12.11.e232263.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2007.00263.x"},{"key":"2025082722521688000_12.11.e232263.5","first-page":"990","article-title":"Pseudoporphyria: discussion of etiologic agents","volume":"13","author":"Beer","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2025082722521688000_12.11.e232263.6","doi-asserted-by":"publisher","DOI":"10.4065\/76.5.488"},{"key":"2025082722521688000_12.11.e232263.7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600893"},{"key":"2025082722521688000_12.11.e232263.8","doi-asserted-by":"crossref","DOI":"10.1097\/00000372-199306000-00001","article-title":"Caterpillar bodies: distinctive, basement membrane-containing structures in blisters of porphyria","volume":"15","author":"Egbert","year":"1993","journal-title":"Am J Dermatopathol"},{"key":"2025082722521688000_12.11.e232263.9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0004563216667965","article-title":"Best practice guidelines on first-line laboratory testing for porphyria","volume":"54","author":"Woolf","year":"2017","journal-title":"Ann Clin Biochem"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:52:25Z","timestamp":1756360345000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":9,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,2]]},"published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1136\/bcr-2019-232263"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232263","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}